Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
June 01, 2024 08:00 ET
|
Molecular Partners
Mechanism of action supported by observed MP0317 localization and immune cell activation in the tumor microenvironmentFavorable and manageable safety profile observed at all tested dose levelsWeekly...
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
May 31, 2024 08:00 ET
|
Novartis Pharma AG
Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR rates at week 48 vs....
Kuntarahoitus laskee liikkeeseen 11 miljoonan euron joukkovelkakirjalainan osana joukkovelkakirjalainaohjelmaa
May 31, 2024 03:00 ET
|
Kuntarahoitus Oyj
Kuntarahoitus OyjPörssitiedote31.5.2024 klo 10.00 Kuntarahoitus laskee liikkeeseen 11 miljoonan euron joukkovelkakirjalainan osana joukkovelkakirjalainaohjelmaa Kuntarahoitus Oyj laskee...
Municipality Finance issues EUR 11 million notes under its MTN programme
May 31, 2024 03:00 ET
|
Municipality Finance Plc
Municipality Finance PlcStock exchange release 31 May 2024 at 10:00 am (EEST) Municipality Finance issues EUR 11 million notes under its MTN programme Municipality Finance Plc issues...
Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024
May 31, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – May 31, 2024 Idorsia Ltd (SIX: IDIA) today announced that data from the Phase 3 study of aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented by Prof....
Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024
May 31, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – May 31, 2024 Idorsia Ltd (SIX: IDIA) today announced that data from the Phase 3 study of aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented by Prof....
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
May 31, 2024 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric...
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
May 30, 2024 18:01 ET
|
Novartis Pharma AG
Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52)1Remibrutinib, an oral Bruton’s...
EPH European Property Holdings PLC announces the Appointment of Christina Spyrou-Katras as Secretary of the Company as well as the Notice for its Annual General Meeting 2024
May 30, 2024 13:00 ET
|
EPH European Property Holdings PLC
30 May 2024, Limassol, Cyprus I Ad hoc announcement pursuant to Art. 53 LR _____________________________________________________________________________________________________________ ...
21.co Launches Wrapped Bitcoin (21BTC) on Solana
May 30, 2024 09:00 ET
|
21Shares
21.co aims to provide simple access to Bitcoin on the Solana blockchain, further enabling deep liquidity on decentralized exchanges, collateral eligibility on lending applications, and...